AstraZeneca first quarter results 2013
- Details
- Category: AstraZeneca
AstraZeneca today announced that the revenue for the first quarter was $6,385 million, down 12 percent at constant exchange rates (CER). Losses of exclusivity for Seroquel IR and Atacand in many markets, and for Crestor in Canada, were the key drivers for the revenue decline. Growth for Symbicort, Brilinta, Iressa and the inclusion of the Amylin diabetes products delivered more than $250 million of revenue growth at CER in the quarter.
Novartis delivered solid performance in the first quarter
- Details
- Category: Novartis
Novartis net sales increased 2% (+4% cc) to USD 14.0 billion in the first quarter, with all divisions contributing to growth. Currency had a negative impact of 2 percentage points. Excluding the impact of patent expiries, underlying sales grew 7%. This was fueled by growth products such as Gilenya, Afinitor, Tasigna, Galvus, Lucentis, Xolair, Arcapta Neohaler/Onbrez Breezhaler and Jakavi, which together contributed USD 4.2 billion or 30% of Group net sales, up 14% over the prior-year period.
Abbott reports first-quarter 2013 results
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced financial results for the first quarter ended March 31, 2013. Worldwide sales of nearly $5.4 billion increased 3.5 percent on an operational basis, consistent with previous guidance, driven by 9.0 percent operational sales growth in Nutrition and 6.4 percent operational sales growth in Diagnostics.
Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies
- Details
- Category: Daiichi Sankyo
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Ranbaxy Laboratories Limited (hereafter, Ranbaxy) today announced synergy in Brazil to expand the business of both companies in the country. As part of this synergy, Ranbaxy will support Daiichi Sankyo's Brazilian subsidiary, Daiichi Sankyo Brasil Farmaceutica Ltda. (hereafter, Daiichi Sankyo Brazil), to enter the branded generics market, in addition to its established business of providing innovative products.
Roche Group posts strong sales growth in the first quarter
- Details
- Category: Roche
Group sales rose 6% to 11.6 billion Swiss francs as demand for Roche's cancer medicines and clinical laboratory products grew strongly in the first three months of the year. Higher sales of Tamiflu due to a severe flu season in North America also supported Roche's performance in the first quarter.
Lundbeck announces positive results for Brintellix™ (vortioxetine)
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) today announced positive results for the REVIVE study, a double-blind randomized study of Brintellix™ (vortioxetine) versus agomelatine in adults with major depression (MDD) who changed antidepressant treatment after an inadequate response to SSRI or SNRI treatment.
Astellas and Ambrx initiate collaboration for discovery and development of antibody drug conjugates for oncology
- Details
- Category: Business
Astellas Pharma Inc. (Tokyo: 4503, "Astellas") entered into a collaboration with Ambrx Inc. ("Ambrx") for the discovery and development of novel antibody drug conjugates ("ADCs"). ADCs allow for the targeted delivery of drugs to the target tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads.
More Pharma News ...
- MedImmune, AstraZeneca's biologics unit, acquires AlphaCore Pharma
- Supreme Court denial of Glivec patent clarifies limited intellectual property protection and discourages future innovation in India
- FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
- Lundbeck and Otsuka further expand their alliance and enter into collaboration
- AstraZeneca settles litigation over CRESTOR patent
- Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies
- Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma